Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Procyon Advisors LLC

Procyon Advisors LLC reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,481 shares of the biopharmaceutical company’s stock after selling 544 shares during the period. Procyon Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $2,479,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of REGN. Rakuten Securities Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter worth $26,000. Fairfield Financial Advisors LTD bought a new stake in Regeneron Pharmaceuticals in the third quarter valued at $37,000. Truvestments Capital LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter valued at $39,000. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at $42,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. JPMorgan Chase & Co. cut their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Bank of America reaffirmed an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Sanford C. Bernstein cut their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Finally, Barclays decreased their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Trading Down 1.7 %

Shares of NASDAQ:REGN opened at $681.58 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a market capitalization of $74.90 billion, a price-to-earnings ratio of 16.87, a PEG ratio of 1.60 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20. The company has a 50 day moving average price of $741.54 and a 200 day moving average price of $952.59.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.